Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Researchers identify genetic causes in nearly 1 in 5 patients with dilated cardiomyopathy

Researchers have identified genetic causes in nearly 1 in 5 patients who suffer a type of heart failure called dilated cardiomyopathy.

28 Mar 2012

CRT-D appropriate for patients with left ventricular dysfunction

Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.

27 Mar 2012

New method to easily identify cause of rare diseases

Sanford Health Children's Research Center researcher, Kyle Roux, PhD, has revealed a new method of research that will allow the cause of disease—particularly rare diseases—to become more easily identified.

23 Mar 2012

New method for in vivo study of unknown selenium metabolism

Spanish and Danish researchers have developed a method for the in vivo study of the unknown metabolism of selenium, an essential element for living beings. The technique can help clarify whether or not it possesses the anti-tumour properties that have been attributed to it and yet have not been verified through clinical trials.

22 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

Japan's MHLW provides reimbursement coverage for MTWA test

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that its Microvolt T-Wave Alternans (MTWA) test received reimbursement coverage from Japan's Ministry of Health, Labor and Welfare (MHLW).

17 Mar 2012

New recovery protocol treats heart failure patients with LVADs

Some patients with advanced heart failure caused by cardiomyopathy, the deterioration of function of the heart muscle, are benefitting from a new recovery protocol at the University of Louisville and Jewish Hospital, a part of KentuckyOne Health.

13 Mar 2012

International effort to define ECG interpretation standards in athletes

On Feb. 13-14, the American Medical Society for Sports Medicine (AMSSM) partnered with the ESC Sports Cardiology Section, the PACES, other leading U.S. cardiologists, BJSM, and F-MARC in an effort to define ECG interpretation standards in athletes and develop a comprehensive online training module for physicians around the world to gain expertise in ECG interpretation and the proper evaluation of ECG abnormalities suggestive of a pathologic cardiovascular disorder.

22 Feb 2012

Combination of key guideline-recommended heart failure therapies improve survival odds

A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvement of up to 90 percent in the odds of survival over two years.

22 Feb 2012

CCF endorses bill to identify students at risk of sudden cardiac death

Senators Frank R. Lautenberg (D-NJ) and Robert Menendez (D-NJ) introduced today during National Heart Month the Cardiomyopathy Health Education, Awareness, Risk Assessment and Training in the Schools (HEARTS) Act to the Senate.

18 Feb 2012

UCSF stem cell study suggests novel strategy for heart attack

A UCSF stem cell study conducted in mice suggests a novel strategy for treating damaged cardiac tissue in patients following a heart attack. The approach potentially could improve cardiac function, minimize scar size, lead to the development of new blood vessels - and avoid the risk of tissue rejection.

16 Feb 2012

TomTec to launch 2D Cardiac Performance Analysis MR software

At the upcoming SCMR meeting in Orlando Florida at February 2nd -5th TomTec introduces its 2D Cardiac Performance Analysis MR software product. The tool to quantify myocardial function and deformation based on regular cardiac MRI cine imaging.

31 Jan 2012

Scientists discover finely tuned mechanism associated with CHD

Scientists at the Gladstone Institutes have identified a finely tuned mechanism by which fetal heart muscle develops into a healthy and fully formed beating heart-offering new insight into the genetic causes of congenital heart disease and opening the door to one day developing therapies to fight this chronic and potentially fatal disorder.

23 Jan 2012

Risk of sudden cardiac arrest while running a marathon is low in the healthy: Study

There have been reports of a marathoner collapsing suddenly with no pulse. Now a large study finds such calamities are rare and usually due to a pre-existing heart problem. The study also found such incidents are increasing as more runners try to go the distance.

12 Jan 2012

Grief and heart attacks linked: Study

Researchers have found that grief might actually break ones heart. A new study shows that people grieving the death of a close loved one could have a heart attack risk that is 20 times higher than normal.

10 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

Home-monitoring interventions may benefit patients with heart failure

Heart failure affects 5.8 million people in the U.S. alone and is responsible for nearly 1 million hospitalizations each year, most resulting from a build-up of body fluid in the lungs and other organs due to the heart's inability to pump effectively. The disease needs to be closely tracked in order to avoid such hospitalizations, and home-monitoring interventions may be especially useful, UCLA researchers say.

4 Jan 2012

Researchers identify candidate genes for histiocytoid cardiomyopathy

Researchers are closing in on a rare genetic disorder causing a heart condition in infants. Histiocytoid cardiomyopathy (HC) often causes sudden death before a child reaches 2 years of age. Gene analysis is helping to narrow the many theories surrounding the genetic basis of HC.

4 Jan 2012